穿心莲的心血管药理作用研究进展

概述了近年来穿心莲的心血管药理研究进展,表明穿心莲具有抗心肌缺血和缺血再灌注损伤、保护血管内皮细胞、调脂、降压、抗动脉粥样硬化和预防血管成形术后再狭窄以及改善血液流变性等作用。     

505神功护膝对膝部红外热象的影响

用ＨＲ－Ⅱ型红外热象仪观察１６例患者戴用５０５神功护膝１ｈ及２ｈ后膝部红外热象变化，并以另一侧膝部及用无药物的护膝作空白对照。统计结果表明，戴用５０５神功护膝２ｈ，不仅使其覆盖的膝部及覆盖区域鹤顶、犊鼻、内膝眼穴温度非常显著升高，Ｐ＜０．００１，也使其药芯边缘可及或接近部位的梁丘、足三里穴温度非常显著升高，Ｐ＜０．００１。这一作用起效较快（１ｈ开始有作用，２ｈ作用显著），首先在药芯中心部位覆盖处（内膝眼）起效，且在２ｈ内随着使用时间延长而升温作用增强。为该护膝药物温经散寒功效提供了直观形象的客观证据。     

如何制订临床研究设计方案

<正> 许多中医临床工作者习惯于在临证工作中抓病例、看疗效,积累一定资料后分析总结。他们还没有认识到在临床试验正式开始之前,进行科研设计、制订研究方案(计划)的重要性,因而其临床观察有很大的盲目性,而且进展缓慢,成果难出,水平较低。搞好临床研究设计,制定一个严密而完整的设计方案,如同在一次战役之前制订作战计划和实施方案,直接关系到研究的进展快慢、资料齐全与否及成果的水平、质量。有志于搞好科研的临床工作者,都应当重视这个基本环节。临床研究设计方案要点中医临床研究设计方案要遵循医学科研设计的基本要求和基本格式,又应注意临床试验的特点和中医学术的特色。设计方案应完整、周密、合理而又切实可行。其一般要点如下。     

水蛭微粉对不稳定性心绞痛血小板活化抑制作用观察

目的:探讨水蛭微粉对不稳定性心绞痛患者血小板活化的抑制作用。方法:80例患者随机分为常规西药治疗组和常规西药加超微粉碎水蛭组。主要观察治疗前后血管性假血友病因子(vWF)、血小板α-颗粒膜蛋白140(GMP-140)水平。结果:两组治疗后vWF、GMP-140水平均有显著改善(P<0.01);且治疗后水蛭组较西药组vWF、GMP-140改善更明显(P<0.01)。结论:水蛭对不稳定性心绞痛患者血小板活化有抑制作用。     

脉心康胶囊治疗血脂异常的疗效观察

目的观察脉心康胶囊对血脂异常病人的降脂疗效。方法将40例血脂异常病人随机分为脉心康组(治疗组)和血脂康组(对照组)各20例,连续给药50d。检测治疗前后临床症状变化以及血脂和载脂蛋白变化。结果治疗组治疗后血清总胆固醇(TC)、低密度脂蛋白(LDL-C)、载脂蛋白(G)[Lp(a)]和ApoB100/ApoAI比值均较治疗前明显降低(P<0.01),且乏力和少寐症状临床症状的改善及降低三酰甘油(TG)的作用均明显优于对照组(P<0.05)。结论脉心康胶囊具有良好的降脂疗效。     

胶质母细胞瘤MGMT基因启动子甲基化与蛋白表达

Objective To study the correlation of MGMT gene promoter methylation and protein expression and their regional variation in different specimens obtained from different regions within the tumor in patients with newly diagnosed glioblastoma. Methods Two to four samples in the same tumor were collected from different regions in 30 patients with newly diagnosed glioblastoma patients. In five patients among them,mutispecimens were obtained under assistance of neuronavigation system during the operation. In all samples,MGMT promoter profile were analyzed by Methylation - specific polymerase - Chain - reaction analysis, MSP ,while MGMT protein expression was detected in tissue sections by immunohistochemistry,IHC. Results MGMT promoter methylation was detected in 43. 56% (44/101) specimens. MGMT protein expression in tissue sections was assessed and scored:(1 :no or positive tumor cells < 10%, 2: ≥ 10% ≤50% ,3: > 50%) ,The rate of MGMT staining with a score 1,2,3 in all of tumor sections was 32. 67% ,43.56% ,23. 76% respectively. No significant correlation between MGMT protein expression and promoter methylation(x2 =2. 905, P =0.088) was found. The regional heterogeneity of MGMT protein expression within the same tumor was in 57% (17/30) patients ;and the regional heterogeneity of gene promoter methylation was in37%(11/30)patients. Conclusions MGMT promoter methylation is probably not the only modulating element in MGMT protein expression. The heterogeneity of MGMT protein expression and its promoter methylation in the same tumor questions their guiding significance in making therapeutic scheme for individual patients with malignant glioma in clinical practice.     

解毒活血中药配伍对载脂蛋白E基因敲除小鼠主动脉NF-κB与MMP-9表达的调控作用

目的 观察解毒活血中药配伍对栽脂蛋白E基因敲除小鼠[apolipoprotein E knocked-outmice,ApoE（-／-）mice]主动脉核因子-κB（NF-κB）和基质金属蛋白酶-9（MMP-9）表达水平的调控作用。方法 13周龄ApoE（-／-）小鼠分为高脂组（给予高脂饲料）和普通饲料组（给予普通饲料）,同时设13周龄C57BL／6J小鼠对照组（给予普通饲料）。19周后进行干预,普通饲料模型组、C57BL／6J小鼠对照组灌服生理盐水,高脂组随机分为解毒组[灌服虎杖苷26．6mg／（kg·d）],活血组[灌服芎芍胶囊110mg／（kg·d）],解毒活血配伍高剂量组（灌服虎杖提取物53．2mg／（kg·d）,芎芍胶囊220mg／（kg·d）];解毒活血配伍中剂量组[灌服虎杖提取物26．6mg／（kg·d）,芎芍胶囊110mg／（kg·d）];解毒活血配伍低剂量组（灌服虎杖提取物13．3mg／（kg·d）,芎芍胶囊55rag／（kg·d）],洛伐他汀组[灌服洛伐他汀3．3mg／（kg·d）],高脂饲料模型组（灌服生理盐水）。17周后,取主动脉做常规石蜡切片,免疫组化观察其NF-κB和MMP-9表达的程度。结果 模型组ApoE（-／-）小鼠主动脉及粥样斑块NF-κB和MMP-9表达明显增加,虎杖苷、芎芍胶囊、洛伐他汀及解毒活血配伍治则的虎杖苷与芎芍胶囊配伍均可降低其主动脉NF-κB和MMP-9表达（P〈0．01）,且以解毒活血配伍高剂量组疗效最好（P〈0．01）。结论 解毒活血配伍可降低ApoE（-／-）小鼠主动脉NF-κB和MMP-9表达,且优于单纯解毒和活血组。